Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 56.95
+0.47 (0.83%)
At close: Jan 22, 2026
Shanghai OPM Biosciences Revenue
Shanghai OPM Biosciences had revenue of 93.78M CNY in the quarter ending September 30, 2025, with 29.80% growth. This brings the company's revenue in the last twelve months to 352.91M, up 22.84% year-over-year. In the year 2024, Shanghai OPM Biosciences had annual revenue of 297.24M with 22.26% growth.
Revenue (ttm)
352.91M
Revenue Growth
+22.84%
P/S Ratio
18.38
Revenue / Employee
1.08M
Employees
328
Market Cap
6.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | 124.97M | 66.45M | 113.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |
| PharmaResources (Shanghai) | 667.47M |